HCW Biologics Inc. (the 'Company” or 'HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

This multi-target blood test "offers the potential for improved patient outcomes through earlier HCC detection," John said ...

July 26, 2024|Duration1:55Loblaw and its parent company, George Weston Ltd., have agreed to pay out $500 million to settle a ...

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...